Part-Time
Social Media Content Evaluator
Telugu
RWS
5,001-10,000 employees
AI-powered language services and localization
No salary listed
New Delhi, Delhi, India
Remote
 Social Media (1) |
|---|
Get referred to RWS
See people who can refer or advise you
- The candidate must currently live in India.
- The candidate must have native-level written and spoken fluency in Telugu.
- The candidate must have access to a reliable, high-speed internet connection and a secure personal computer or laptop.
- The candidate must be able to strictly follow detailed photography and data entry guidelines.
- Watch and analyze short-form video clips to identify all languages present in spoken audio and on-screen text.
- Verify and validate that media content aligns with the target locale, including authentic target-language use and relevant cultural context.
- Generate accurate ground-truth labels using internal classification tools according to strict project guidelines.
- Ensure high data quality and consistency for training automated machine-learning models.
- Previous experience in data annotation, content moderation, translation, transcription, or linguistic quality assurance is preferred.
RWS Holdings plc provides language services and technology solutions on a global scale for sectors including aerospace, defense, automotive, life sciences, and more. Its offerings span localization, content management, artificial intelligence, and intellectual property, delivered through AI-powered language services paired with human expertise. Clients engage through service contracts and technology licensing to enable multilingual digital experiences and streamline processes. The company differentiates itself by serving a wide range of industries with tailored, compliant solutions that integrate AI, content management, and IP capabilities under one umbrella. Its goal is to help businesses overcome language barriers and optimize operations across multilingual environments.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Chalfont St Peter, United Kingdom
Founded
1958
Get referred to RWS
See people who can refer or advise you
Simplify's Take
What believers are saying
- H1 2026 revenue rose 7% constant currency and operating profit grew 28%.
- July 2026 launches in Trados and eCOA widen cross-sell into pharma and life sciences.
- Obviously added £2 billion addressable market and management upgraded FY2026 revenue guidance.
What critics are saying
- Smartcat, DeepL, and memoQ compress pricing and threaten Trados desktop share by 2027.
- H1 2026 gross margin fell to 41.6% as lower-margin TrainAI outgrew services.
- Acolad integration and £40 million consideration raise execution risk through 2027.
What makes RWS unique
- Trados Studio 2026 embeds Language Weaver Pro and supports regulated workflows.
- RWS combines localization, IP protection, and eCOA services under one enterprise platform.
- Its Cultural Intelligence Layer and 250,000 specialists anchor quality in complex languages.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Remote Work Options
Company News
Rockworth's H1 review. With four completed deals announced, and continued buyer appetite for high-quality acquisitions, it's been a strong start to 2026. August 7, 2026 The first half of 2026 has seen continued activity across the mid-market, with high-quality businesses attracting interest from both strategic acquirers and financial investors. At Rockworth, Rockworth Management Partners Ltd has supported clients across a broad range of sectors and transaction types. In this H1 review, Rockworth Management Partners Ltd highlight four successful transactions Rockworth Management Partners Ltd has announced so far this year. These deals demonstrate the range of objectives that can be achieved through a carefully considered transaction, whether that means securing an exit, supporting the next phase of growth, or enabling shareholders to focus on other strategic priorities. Rockworth acted as lead sell-side adviser to the shareholders of legal technology business Obviously on its sale to RWS Holdings plc, a listed AI solutions group. The deal comprises £16.5m of initial cash consideration and up to £23.5m of contingent consideration payable over three years, taking the total potential consideration to £40m. Rockworth acted as lead adviser to the shareholders of Fendequip, a manufacturer of mooring products for superyachts, on its investment partnership with Trusta Industries. Trusta is a UK industrial group with a "buy and own forever" philosophy. The founders will continue to lead Fendequip, with strategic support from Trusta, as the business enters its next phase of growth. Rockworth advised DGL International on the sale of the Craig & Rose brand to Benjamin Moore, the premium paint and coatings company owned by Berkshire Hathaway. The transaction brings together two heritage paint brands and supports Benjamin Moore's international growth ambitions. It also enables DGL International to focus on other strategic priorities across the UK and Europe. Rockworth advised the shareholders of Tolley, a specialist consultancy, on the sale of their business to G&L Scientific Group. Tolley supports pharmaceutical and biotech companies through health technology assessment and reimbursement, including submissions to NICE and the Scottish Medicines Consortium. The management team will continue to lead the business as part of G&L Scientific's expanding group of market access consultancies across Europe. With momentum in M&A continuing into the second half of 2026, Rockworth Management Partners Ltd expect strong businesses with clear growth prospects to remain attractive to both strategic and financial buyers. If you are considering selling your business, securing investment or exploring other strategic options, its team would welcome a confidential, no-obligation conversation about your objectives and the opportunities available Get the latest news from Rockworth, plus guidance on topics including building value, raising investment and selling businesses.
RWS Holdings, a London-listed AI solutions company, has agreed to acquire Acogroup, parent company of language services provider Acolad, for £22.4 million ($26 million) in enterprise value. Total consideration is £40.2 million, including roughly £17.8 million for cash held at closing. Founded in 1995 and headquartered near Paris, Acolad operates across 22 countries in Europe and North America with about 1,200 employees. The company reported revenue of £182 million and adjusted EBITDA of £13 million for the year ending 31 December 2025. Roughly half of Acolad's revenue comes from regulated industries, whilst about 75% derives from localisation services. RWS said the deal would extend its AI platforms to more enterprise clients, particularly in Western Europe. The transaction is expected to close in the first half of RWS's 2027 fiscal year, pending regulatory approvals.
RWS launches new linguistic validation service to significantly reduce clinical trial timelines. New service brings critical eCOA trial services together under one program team to speed global studies. Maidenhead, UK 7/14/2026 9:00:00 AM RWS (AIM: RWS.L), a global AI solutions company, today launched a new tech-enabled eCOA translation and linguistic validation service designed to help pharmaceutical companies, clinical research organizations (CROs) and eCOA providers reduce delays in global clinical trials. The service brings together COA licensing, source validation, multilingual translation, Trados-enabled eCOA migration, intelligent workflows, rater training and dedicated program management under a single, integrated operating model - delivered by one program team with end-to-end governance and a single point of accountability across the entire COA lifecycle.
RWS, a global AI solutions company, has launched a new tech-enabled eCOA translation and linguistic validation service aimed at reducing delays in global clinical trials. The service integrates COA licensing, source validation, multilingual translation, eCOA migration, rater training, and programme management under a single operating model. The new offering addresses delays caused by managing these functions across multiple vendors. A dedicated programme team oversees the entire process, from licensing through to global deployment, providing unified governance and accountability. RWS has expanded its digital health portfolio to include rater training as part of this launch. The company is also investing in AI-powered tools to automate repetitive tasks whilst maintaining scientific rigour and regulatory compliance. RWS serves over 80 of the world's top 100 brands and is headquartered in the UK.
RWS launches new linguistic validation service to significantly reduce clinical trial timelines. RWS July 14, 2026 New service brings critical eCOA trial services together under one program team to speed global studies MAIDENHEAD, England, July 14, 2026 /PRNewswire/ - RWS (AIM: RWS.L), a global AI solutions company, today launched a new tech-enabled eCOA translation and linguistic validation service designed to help pharmaceutical companies, clinical research organizations (CROs) and eCOA providers reduce delays in global clinical trials. The service brings together COA licensing, source validation, multilingual translation, Trados-enabled eCOA migration, intelligent workflows, rater training and dedicated program management under a single, integrated operating model - delivered by one program team with end-to-end governance and a single point of accountability across the entire COA lifecycle. Global clinical trials depend on precise timing, and language is often one of the greatest pressure points. In a global study, every week counts: sponsors need to move from instrument access to eCOA go-live without putting study start-up, site activation or regulatory submissions at risk. Yet many organizations still manage licensing, translation, eCOA migration and rater training across multiple vendors, systems and disconnected workstreams. The result is familiar - handoffs multiply, accountability blurs, visibility narrows, and small delays compound into significant operational and regulatory risk. RWS's service addresses this by redesigning the delivery model around dedicated program management and intelligent workflows. A single leadership team owns planning, execution, communication, risk management and delivery at every stage, from licensing through to global deployment. "Bringing eCOA translation, linguistic validation and rater training together under one program team is exactly the kind of service model global clinical trials need," said Martial Marcotti, EVP & Chief Product Officer at Kayentis, a leading eCOA vendor. "Across many studies and therapeutic areas, we've come to rely on RWS as a trusted partner because they understand both the operational pressure sponsors face and the quality standards regulated research demands. An integrated approach like this can simplify global study execution, reduce handoffs and help sponsors move faster without compromising endpoint quality, compliance or the patient experience." As part of this transformation, RWS has expanded its digital health portfolio to include rater training, bringing together COA licensing, source validation, linguistic validation, eCOA migration, and rater training into one integrated delivery program. By removing traditional service silos, sponsors benefit from streamlined communication, consistent governance, simplified vendor management, and improved coordination from instrument acquisition through study execution. "Clinical teams shouldn't have to choose between speed and scientific standards," said Dan Herron, Global Vice President, Digital Health at RWS. "For more than a decade, the industry has relied on fragmented delivery models for licensing, source validation, linguistic validation, eCOA migration and rater training. We've reimagined that approach by bringing every service together under a single program - creating a faster, more connected and more scalable model that helps sponsors reduce complexity, protect endpoint quality and accelerate global study execution." RWS is also investing in AI-powered tools and smart automation to augment subject matter experts - automating repetitive tasks, strengthening quality oversight and accelerating delivery while preserving the scientific rigor and regulatory compliance global research demands. RWS is a global AI solutions company empowering the world's most trusted enterprise AI. Its proprietary Cultural Intelligence Layer, powered by 250,000 data specialists, cultural and language experts and deep domain professionals, backed by 45+ patents, makes enterprise AI culturally fluent, contextually accurate and secure, ensuring every interaction reflects a brand's tone, context and customer values. Through its Generate, Transform and Protect segments, Nsfre deliver intelligent content, enterprise knowledge, large-scale localization and IP protection for global growth. Trusted by 80+ of the world's top 100 brands, RWS provides the confidence, governance and expertise organizations need to deploy AI safely, responsibly and at scale. Headquartered in the UK, RWS is listed on AIM. More information: rws.com. SOURCE RWS Distributed by PR Newswire / Cision.